the efficacy of topical erythropoietin treatment on healing of second degree burned cutaneous burned wounds

Evaluation of the effect of topical erythropoietin in comparison with placebo on the healing of grade 2 burn wounds

Erythropoietin and placebo creams will be made in the Pharmaceutics Laboratory of Yazd School of Pharmacy. Patients with second-degree burns referred to Yazd Martyrs Hospital in Yazd will be included in the study. Patients will receive erythropoietin or placebo creams once a day for two weeks. The steps will be covered by the patient, physician, and evaluators. In this way, the first executor of the sequence plan determines the allocation of people according to the order in which the sick people enter the study and puts the tablets in boxes of the same shape for the patient to consume, and identifies them with codes A or B.

Patients with second-degree burns referred to Yazd Martyrs Hospital in Yazd will be included in the study. Patients will receive erythropoietin or placebo creams once a day for two weeks.

Inclusion criteria include referral to the burn center in the first 24 hours after the burn, having a second-degree and deep burn that covers less than 10% of the body surface, no concomitant disease that delays the healing process (such as diabetes, chronic kidney disease, malignancy, and chronic use of corticosteroids), lack of respiratory burns as well as burns with chemicals or electricity, lack of burns on the face, perineum, and hands.

One group is the erythropoietin cream recipient, the other is the placebo cream recipient.

Comparison of wound healing percentage in two groups on days 1, 5, 9, 13

Patients were randomly assigned to two groups of 24 controls or interventions by the permutation block method. Twelve blocks of four are considered. Generation of random codes using Permuted Block Randomization method will be done with the help of Random allocation software (version 1). The first person who is eligible to enter the study is given number one and likewise, the last eligible person is given number 48. By using the software-generated table, patients receive each intervention A or B (Each of the letters A and B will be installed on similar containers of the interventions). In order to consider blinding in random allocation, the list is given to another person outside the study and using short message service (SMS) before assigning the type of treatment according to the number of eligible people is asked and thus people enter the study.

The steps will be covered from the perspective of the patient, the treating physician, and the assessors. The first presenter identifies the sequence of assignments of patients according to the order of entry of the patients into the study, and puts the erythropoietin and placebo creams (identical from color, odor, and shape) into one-size boxes for patient use, and identifies them with A or B codes. The student then delivers the drugs to each individual patient